In kidney disease, JD5037 has been shown to improve diabetic nephropathy, by improving podocyte function and led to the production of a hybrid/third-generation CB1 antagonist, MRI-1867, which has been shown to improve obesity-induced CKD [54,77]. Here, CNR1 is linked to chronic kidney disease.